Gordonmd Global Investments LP is an SEC-registered investment adviser based in Beverly Hills, CA that reports managing 1 hedge fund on Form ADV. It reports $322.3 million in regulatory assets under management. Its private funds, of all types, hold $322.3 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +14.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +14.1% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $322.3 millionForm ADV Item 5.F
- Gross assets of private funds
- $322.3 millionAll private fund types, Form ADV
- Hedge funds managed
- 14 private funds in total
- Employees
- 7Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 316751
- Latest Form ADV
- 03/26/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +18.6% | +14.8% |
| Q1 2026 | -3.8% | -4.6% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 14 share positions ($166,469,374) reported by GordonMD Global Investments LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Pyxis Oncology Inc21.75%
- Kyverna Therapeutics Inc18.47%
- Teva Pharmaceutical Inds LTD9.03%
- Celldex Therapeutics Inc New5.45%
- Tango Therapeutics Inc5.42%
- Vir Biotechnology Inc5.40%
- Adarx Pharmaceuticals Inc5.39%
- Allogene Therapeutics Inc5.09%
- Bausch Plus Lomb Corp4.86%
- Editas Medicine Inc4.83%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Pyxis Oncology Inc | $36,212,648 | 21.75% | 15,541,909 | +55.03% |
| Kyverna Therapeutics Inc | $30,744,962 | 18.47% | 4,521,318 | +6.51% |
| Teva Pharmaceutical Inds LTD | $15,028,992 | 9.03% | 379,520 | New |
| Celldex Therapeutics Inc New | $9,065,725 | 5.45% | 279,720 | Unchanged |
| Tango Therapeutics Inc | $9,021,651 | 5.42% | 1,852,495 | New |
| Vir Biotechnology Inc | $8,983,711 | 5.40% | 803,552 | -40.63% |
| Adarx Pharmaceuticals Inc | $8,973,000 | 5.39% | 450,000 | New |
| Allogene Therapeutics Inc | $8,476,800 | 5.09% | 5,298,000 | Unchanged |
| Bausch Plus Lomb Corp | $8,083,024 | 4.86% | 475,472 | -17.09% |
| Editas Medicine Inc | $8,036,390 | 4.83% | 3,127,000 | Unchanged |
| Incyte Corp | $6,198,558 | 3.72% | 51,080 | +17.97% |
| Taysha Gene Therapies Inc | $6,187,600 | 3.72% | 248,000 | -65.71% |
| Amgen Inc | $6,116,953 | 3.67% | 14,512 | -28.20% |
| Scholar Rock Hldg Corp | $5,339,360 | 3.21% | 110,500 | -16.60% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 3 new positions, 5 sold out, 3 increased, 5 reduced and 3 unchanged.
Number of positions (a count, not dollars)
- New positions3
- Increased3
- Unchanged3
- Reduced5
- Sold out5
New positions
| Stock | Value | Shares |
|---|---|---|
| Teva Pharmaceutical Inds LTD | $15,028,992 | 379,520 |
| Tango Therapeutics Inc | $9,021,651 | 1,852,495 |
| Adarx Pharmaceuticals Inc | $8,973,000 | 450,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Teva Pharmaceutical Inds LTD | $16,360,991 | 2,402,495 |
| Ultragenyx Pharmaceutical In | $9,653,082 | 289,101 |
| Sionna Therapeutics Inc | $5,982,640 | 136,000 |
| Crinetics Pharmaceuticals In | $4,751,779 | 126,985 |
| Insmed Inc | $3,047,946 | 28,587 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Pyxis Oncology Inc | +5,517,000 | +55.03% | $36,212,648 | 15,541,909 |
| Kyverna Therapeutics Inc | +276,500 | +6.51% | $30,744,962 | 4,521,318 |
| Incyte Corp | +7,780 | +17.97% | $6,198,558 | 51,080 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Taysha Gene Therapies Inc | -475,185 | -65.71% | $6,187,600 | 248,000 |
| Vir Biotechnology Inc | -550,000 | -40.63% | $8,983,711 | 803,552 |
| Amgen Inc | -5,700 | -28.20% | $6,116,953 | 14,512 |
| Bausch Plus Lomb Corp | -98,000 | -17.09% | $8,083,024 | 475,472 |
| Scholar Rock Hldg Corp | -22,000 | -16.60% | $5,339,360 | 110,500 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. | 13G amendment | 7.34% | 4,521,318 | Nov 16, 2026 | SEC.gov ↗ |
| Pyxis Oncology, Inc. | 13G amendment | 16.4% | 20,441,948 | Oct 9, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 9, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private equity funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Mar 20, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures